Page 1 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Coronary Artery Disease (CAD)  
- Coronary Artery Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention  
- Dual Antiplatelet Therapy (DAPT)  
- Cardiovascular Angiography  
- Cardiovascular Interventions  
- Duration of Dual Antiplatelet Therapy in Coronary Artery Disease  

Page 2 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Acute Coronary Syndromes (plural)  
- Angina, unstable  
- Anticoagulants  
- Antiplatelet therapy  
- Aspirin  
- Atrial fibrillation  
- Beta‑blocker therapy  
- Cardiogenic shock  
- Cardiovascular diseases  
- Catheterization laboratory  
- Coronary angiography  
- Coronary artery disease (CAD)  
- Coronary syndrome  
- Emergency medical services (EMS)  
- Fibrinolytic agents / fibrinolytic therapy  
- Glycoprotein IIb/IIIa inhibitors  
- Hemorrhage  
- Intracoronary imaging  
- Intravenous P2Y12 inhibition  
- Major adverse cardiovascular events (MACE)  
- Morphine  
- Multivessel CAD (multivessel coronary artery disease)  
- Myocardial infarction (MI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Oral P2Y12 inhibitors  
- Oxygen therapy  
- Percutaneous coronary intervention (PCI)  
- Prehospital assessment / prehospital care  
- Primary percutaneous coronary intervention (PPCI)  
- Revascularization  
- Renin‑Angiotensin‑Aldosterone System (RAAS) inhibitors  
- Risk stratification tools  
- Risk (general)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Time factors (time‑to‑treatment)  
- Treatment outcome  
- Vascular access approach for PCI  
- Aspirational thrombectomy (aspiration thrombectomy)  
- CABG surgery (coronary artery bypass graft)  
- Regional systems of STEMI care  
- Routine invasive approach (vs. selective invasive approach)  
- Standard medical therapies for STEMI and NSTE‑ACS  
- Cardiac arrest management  
- Analgesics (pain management)  
- Lipid management  
- Parenteral anticoagulation  
- Reperfusion strategies (including fibrinolysis and PCI)  
- In‑hospital assessment of ACS patients  
- Emergency medical services (EMS) considerations for ACS  
- Prehospital management considerations for suspected ACS  
- Revascularization in ACS with cardiogenic shock  

*(All terms are presented as distinct, heart‑disease‑related concepts extracted from the provided guideline text.)*

Page 3 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Cardiogenic Shock  
- Mechanical Complications (of ACS)  
- Electrical Complications (of ACS)  
- Sudden Cardiac Death  
- Pericarditis (post‑MI)  
- Myocardial Infarction (MI)  
- Left Ventricular (LV) Thrombus  
- Cardiac Intensive Care Unit (CICU)  
- Anemia in ACS  
- Telemetry  
- Non‑invasive Diagnostic Testing  
- Discharge Planning  
- Patient Education  
- Post‑discharge Follow‑up / Systems of Care Coordination  
- Cardiac Rehabilitation  
- Dual Antiplatelet Therapy (DAPT)  
- Percutaneous Coronary Intervention (PCI)  
- Antiplatelet Therapy  
- Anticoagulation (post‑discharge)  
- Lipid‑lowering Therapy / Lipid Levels Reassessment  
- Sodium‑Glucose Co‑Transporter‑2 (SGLT‑2) Inhibitors  
- Glucagon‑Like Peptide‑1 (GLP‑1) Receptor Agonists  
- Chronic Colchicine Therapy  
- Immunization (post‑ACS)  
- P2Y12 Inhibitors (e.g., ticagrelor, prasugrel, clopidogrel)  
- Aspirin  
- Ticagrelor  
- Prasugrel  
- Clopidogrel  
- Proton Pump Inhibitor (PPI)  
- High‑Intensity Statin Therapy  
- Ezetimibe  
- Evolocumab  
- Alirocumab  
- Inclisiran  
- Bempedoic Acid  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Non‑ST‑segment Elevation ACS (NSTE‑ACS)  
- ST‑segment Elevation ACS (STEMI) – implied in guideline context  
- Invasive Strategy (early angiography/revascularization)  
- Revascularization (PCI or CABG)  
- Radial Access Approach (vs. femoral)  
- Femoral Access Approach  
- Intracoronary Imaging (IVUS/OCT)  
- Complex Coronary Lesions  
- Major Adverse Cardiovascular Events (MACE)  
- Gastrointestinal Bleeding Risk  
- Bleeding Risk Management  
- Hospitalization (in‑patient management)  
- Long‑Term Anticoagulation  
- P2Y12 Inhibitor Monotherapy (post‑PCI)  
- Risk Stratification (ischemic vs. bleeding risk)  
- Mechanical Circulatory Support (MCS) in ACS with cardiogenic shock.

Page 4 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation ACS (NSTEMI/unstable angina)  
- Complete revascularization  
- Coronary artery bypass graft surgery (CABG)  
- Multivessel percutaneous coronary intervention (PCI)  
- Coronary artery disease (CAD)  
- Multivessel disease  
- Non‑culprit stenoses  
- Cardiogenic shock  
- Emergency revascularization  
- Culprit vessel  
- Non‑infarct‑related arteries  
- Microaxial flow pump (e.g., Impella)  
- Acute myocardial infarction (AMI)  
- Bleeding complications  
- Limb ischemia  
- Renal failure / acute kidney injury  
- Vascular access  
- Weaning of mechanical circulatory support  
- Red blood cell transfusion  
- Hemoglobin level (target 10 g/dL)  
- Anemia (acute or chronic)  
- Secondary prevention  
- Fasting lipid panel  
- Lipid‑lowering therapy (e.g., statins)  
- Cardiac rehabilitation (including home‑based programs)  
- Cardiovascular disease (CVD)  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Guideline methodology / clinical practice guidelines  
- Shared decision‑making  
- Comorbid conditions / comorbidities  
- Value assessment (cost‑value considerations)  
- Drug, device, or intervention evaluation.

Page 5 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Angina, unstable  
- Anticoagulants  
- Aspirin  
- Atrial fibrillation  
- Cardiovascular diseases  
- Coronary artery disease (CAD)  
- Coronary syndrome  
- Fibrinolytic agents  
- Major adverse cardiovascular events (MACE)  
- Myocardial infarction (MI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- ST‑elevation myocardial infarction (STEMI)  
- Percutaneous coronary intervention (PCI)  
- Revascularization  
- Morphine (as a treatment for chest pain)  
- Hemorrhage (as a complication)  
- Emergency medical services (EMS) – prehospital care for cardiac events  
- Guideline‑directed medical therapy (GDMT)  
- Risk assessment (cardiovascular risk)  
- Treatment outcome (cardiac outcomes)  

Page 6 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Acute Coronary Syndromes (ACS)  
- Acute Myocardial Infarction (AMI)  
- Type 1 myocardial infarction  
- Type 2 myocardial infarction  
- ST‑Elevation Myocardial Infarction (STEMI)  
- ST‑segment elevation myocardial infarction (full phrase)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTEMI)  
- Coronary Artery Disease (CAD)  
- Coronary Heart Disease (CHD)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention  
- Dual Antiplatelet Therapy (DAPT)  
- Reperfusion therapy  
- Secondary prevention (post‑MI)  
- Coronary artery revascularization  
- Cardiovascular mortality  
- Cardiovascular morbidity  
- Chest pain (typical AMI symptom)  
- Non‑chest‑pain symptoms (atypical ACS presentation)  
- Cardiovascular risk factors (e.g., hypertension, hyperlipidemia, diabetes, smoking)  
- Racial disparities in CAD/MI incidence and outcomes  
- Sex‑related disparities in ACS presentation, treatment, and outcomes  
- Guideline‑directed medical therapy (GDMT)  
- Cardiovascular imaging  
- Cardiovascular surgery (cardiovascular surgeons)  
- Economic impact of myocardial infarction (direct medical costs, indirect productivity loss)  

*(All terms are directly mentioned or implied in the provided guideline excerpt and are central to the clinical management of heart disease.)*

Page 7 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Obstructive Coronary Artery Disease  
- Coronary Artery Revascularization  
- Chronic Coronary Disease  
- Chest Pain (Angina)  
- Cardiogenic Shock  
- SHOCK Stage Classification  
- Mechanical Complications of Acute Myocardial Infarction  
- Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock  
- Left Ventricular Thrombus  
- Heart Failure  
- Atrial Fibrillation (AF)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- High Blood Pressure / Hypertension  
- Blood Cholesterol / Hypercholesterolemia  
- Primary Prevention of Cardiovascular Disease  
- Stroke  
- Transient Ischemic Attack (TIA)  
- Home‑Based Cardiac Rehabilitation  
- Out‑of‑Hospital Cardiac Arrest  
- Cardiac Catheterization Laboratory Management  
- Classification of Cardiogenic Shock (SCAI)  
- Evaluation and Diagnosis of Chest Pain  
- Management of Patients with Chronic Coronary Disease  
- Management of Patients at Risk for and with Left Ventricular Thrombus  
- Management of Heart Failure (HFSA)  
- Management of Atrial Fibrillation  
- Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults  
- Management of Blood Cholesterol (Lipid Management)  

*Additional guideline‑related classification terms (useful for context):*  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)  
- PICO[TS] Structure  

These terms capture the primary heart‑disease conditions, interventions, and related clinical concepts presented in the guideline excerpt.

Page 8 Extracted Terms:
- ACEi (angiotensin‑converting enzyme inhibitor)  
- ACS (acute coronary syndromes)  
- AF (atrial fibrillation)  
- AMI (acute myocardial infarction)  
- ARB (angiotensin receptor blocker)  
- ASCVD (atherosclerotic cardiovascular disease)  
- CABG (coronary artery bypass grafting)  
- CAD (coronary artery disease)  
- CCD (chronic coronary disease)  
- CDP (clinical decision pathway)  
- CICU (cardiac intensive care unit)  
- CR (cardiac rehabilitation)  
- cTn (cardiac troponin)  
- CVD (cardiovascular disease)  
- DAPT (dual antiplatelet therapy)  
- DOAC (direct oral anticoagulant)  
- ECG (electrocardiogram)  
- FDA (US Food and Drug Administration)  
- FFR (fractional flow reserve)  

Page 9 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Unstable Angina  
- Non‑ST‑segment Elevation Myocardial Infarction (NSTEMI)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI)  
- Type 1 MI  
- Type 2 MI  
- MINOCA (MI with Non‑obstructive Coronary Artery Disease)  
- Non‑obstructive Coronary Artery Disease  
- Atherosclerotic Plaque Rupture  
- Plaque Erosion  
- Plaque Instability  
- Lipid Accumulation  
- Inflammation of Atherosclerotic Plaque  
- Coronary Artery Thrombosis  
- Microemboli  
- Coronary Artery Spasm  
- Coronary Artery Dissection  
- Embolism  
- Myocardial Ischemia  
- Subendocardial Ischemia  
- Transmural Myocardial Ischemia  
- Myocardial Necrosis (Myonecrosis)  
- High‑sensitivity Cardiac Troponin (hs‑cTn)  
- First Medical Contact (FMC)  
- Glucagon‑like Peptide‑1 (GLP‑1)  
- Heart Failure (HF)  
- Intra‑aortic Balloon Pump (IABP)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Intravascular Ultrasound (IVUS)  
- Low‑density Lipoprotein (LDL)  
- Low‑density Lipoprotein Cholesterol (LDL‑C)  
- Left Ventricle (LV)  
- Left Ventricular Ejection Fraction (LVEF)  
- Major Adverse Cardiovascular Event (MACE)  
- Mechanical Circulatory Support (MCS)  
- Multivessel Disease (MVD)  
- Non‑ST‑segment Elevation ACS (NSTE‑ACS)  
- Optical Coherence Tomography (OCT)  
- Odds Ratio (OR)  
- Percutaneous Coronary Intervention (PCI)  
- Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Proton Pump Inhibitor (PPI)  
- Quality of Life (QOL)  
- Randomized Controlled Trial (RCT)  
- Return of Spontaneous Circulation (ROSC)  
- Sodium‑glucose Cotransporter‑2 (SGLT‑2)  
- Unfractionated Heparin (UFH)  
- Venoarterial Extracorporeal Membrane Oxygenation (VA‑ECMO)  
- Chest Pain  
- Coagulation Cascade  
- Epicardial Vessels  
- Coronary Circulation  

Page 10 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial ischemia  
- Cardiovascular complications  
- Recurrent cardiovascular events  
- Chronic Coronary Disease (CCD)  
- Acute myocardial infarction (AMI)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation ACS (NSTE‑ACS)  
- Primary percutaneous coronary intervention (PPCI)  
- Percutaneous coronary intervention (PCI)‑capable hospital  
- Emergency medical services (EMS)  
- First medical contact (FMC)  
- FMC‑to‑first‑device time  
- 12‑lead electrocardiogram (ECG)  
- Serial ECGs  
- ST‑segment depression  
- T‑wave inversion  
- R wave / R‑S ratio > 1  
- ST‑segment elevation (≥1 mm in ≥2 contiguous leads; ≥2 mm in men < 40 y; ≥1.5 mm in women)  
- Posterior leads (V7‑V9)  
- Left circumflex occlusion  
- Left bundle‑branch block (LBBB)  
- New LBBB  
- Acute pericarditis (ECG mimic)  
- Left ventricular hypertrophy (LVH) (ECG mimic)  
- Brugada syndrome (ECG mimic)  
- Right ventricular pacing (ECG mimic)  
- Takotsubo syndrome (ECG mimic)  
- Early repolarization (ECG mimic)  
- Cardiac catheterization team  
- Arrhythmias  
- Cardiac arrest  
- Reperfusion therapy  
- Risk stratification  
- Long‑term management (post‑ACS)  
- Discharge medications (antiplatelet, anticoagulant, statin, β‑blocker, ACE‑I/ARB, etc.)  
- Inflammatory milieu (post‑ACS)  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline (2023)  
- Pre‑hospital assessment and management  
- Triage strategy  
- Vital signs assessment  
- Focused history and physical examination  
- Electrocardiographic interpretation for suspected ACS  
- ST‑segment changes in other conditions (pericarditis, LVH, LBBB, Brugada, pacing, Takotsubo, early repolarization)  

*(All terms above are key heart‑disease‑related concepts extracted from the provided guideline excerpt.)*

Page 11 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- ST‑segment elevation (electrocardiographic criteria)  
- 12‑lead electrocardiogram (12‑lead ECG)  
- Pre‑hospital ECG acquisition  
- Primary percutaneous coronary intervention (PPCI)  
- Percutaneous coronary intervention (PCI)‑capable facility  
- Coronary reperfusion  
- Heart failure (HF)  
- Ventricular arrhythmias  
- Cardiogenic shock  
- Mortality (death) risk  
- Patient triage (based on ECG findings)  
- Electrocardiographic tracings transmission  
- Reperfusion time  
- Trained EMS personnel / paramedics  
- Electrocardiographic classification of ACS  
- Acute myocardial infarction (MI)  
- Cardiovascular emergency management  
- Guideline recommendations (Section 8, “Cardiogenic Shock Management”)  

Page 12 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation ACS (NSTE‑ACS)  
- Electrocardiogram (ECG) / electrocardiographic changes  
- ST‑segment elevation  
- ST‑segment depression  
- Posterior ECG leads (V7‑V9)  
- Primary percutaneous coronary intervention (PPCI)  
- Percutaneous coronary intervention (PCI)  
- Time‑to‑device / FMC‑to‑first‑device time  
- Door‑to‑balloon time  
- Catheterization laboratory activation  
- Emergency department (ED) bypass  
- Regional STEMI care system  
- Myocardial salvage  
- Mortality (1‑year mortality)  
- Acute myocardial infarction (AMI)  
- Type 1 myocardial infarction (type 1 MI) – atherothrombosis, plaque rupture/erosion  
- Type 2 myocardial infarction (type 2 MI) – supply‑demand mismatch  
- Type 3 myocardial infarction (type 3 MI) – cardiac death with ischemic changes/ventricular arrhythmia  
- Type 4a myocardial infarction – peri‑PCI MI (≤48 h)  
- Type 4b myocardial infarction – post‑PCI stent/scaffold thrombosis  
- Type 4c myocardial infarction – post‑PCI stent restenosis  
- Type 5 myocardial infarction – peri‑CABG MI (≤48 h)  
- Coronary artery bypass grafting (CABG)  
- Myocardial infarction with non‑obstructive coronary arteries (MINOCA)  
- Spontaneous coronary artery dissection (SCAD)  
- Atherothrombosis  
- Plaque disruption (rupture, erosion)  
- Ischemic symptoms / myocardial ischemia  
- Ventricular arrhythmia  
- Pre‑hospital ECG / serial ECGs  
- Emergency medical services (EMS)  
- PCI‑capable hospital  
- Non‑PCI‑capable hospital  
- Reperfusion therapy  
- System‑level interventions (e.g., pre‑hospital catheterization activation)  
- Clinical suspicion of ACS  
- Chest pain evaluation  
- Cardiac biomarkers  
- Autopsy‑diagnosed MI  

Page 13 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑elevation Myocardial Infarction (STEMI)  
- Non‑ST‑elevation ACS (NSTE‑ACS)  
- Acute Myocardial Infarction (AMI) / Myocardial Infarction (MI)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Cardiac troponin (cTn) – Troponin I, Troponin T  
- 12‑lead Electrocardiogram (ECG) / Serial ECG  
- Ischemic ECG changes (ST‑segment elevation, ST‑segment depression, T‑wave inversion)  
- Chest pain  
- Cardiogenic shock  
- Hemodynamic instability  
- Mechanical complications of MI  
- Cardiac catheterization  
- Fibrinolytic therapy (thrombolysis)  
- Reperfusion therapy (primary PCI, thrombolysis)  
- Point‑of‑care ultrasound (POCUS) / Urgent echocardiography  
- Right‑sided ECG leads (right ventricular involvement)  
- Posterior STEMI (posterior lead ECG)  
- Anteroseptal leads (V1‑V3)  
- Inferior STEMI  
- Major adverse cardiovascular events (MACE)  
- Clinical decision pathways (CDPs)  
- National Cardiovascular Data Registry (NCDR) ACTION  
- 99th percentile upper reference limit (URL) for troponin  
- Biomarker of myocardial injury  
- High‑sensitivity assay vs. conventional troponin assay  
- Dynamic ECG abnormalities  
- Serial troponin measurements (1‑2 h for hs‑cTn, 3‑6 h for conventional cTn)  
- Clinical suspicion of ACS  
- Emergency Department (ED) presentation  
- History and physical examination for ACS  
- Risk stratification / patient exercise capacity  
- Patient preference in diagnostic testing  
- Electrocardiographic findings (ST‑segment changes, T‑wave inversions)  
- Timing of ECG acquisition (within 10 minutes)  
- Repeated ECG for evolving changes  
- Evidence‑based guidelines (AHA/ACC)  

Page 14 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Acute coronary syndrome (singular)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Myocardial infarction (MI)  
- Cardiac troponin (cTn)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Clinical decision pathway (CDP)  
- Chest pain guideline (2021 AHA/ACC/Multisociety Chest Pain Guideline)  
- Low‑risk, intermediate‑risk, high‑risk categories (risk stratification)  
- Initial assessment (of patients with suspected ACS)  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- Multisociety guideline  
- Coronary artery disease (implied by “coronary” in ACS)  
- Cardiovascular risk assessment  
- Evidence‑based recommendations (Class of Recommendation)  

Page 15 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial ischemia  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Cardiac troponin (cTn)  
- 99th percentile upper reference limit  
- Limit of quantification (LoQ)  
- Delta (Δ) hs‑cTn (change in troponin)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Unstable angina  
- GRACE Risk Score (Global Registry of Acute Coronary Events)  
- TIMI Risk Score (Thrombolysis in Myocardial Infarction)  
- Killip classification / Killip class  
- Major adverse cardiovascular events (MACE)  
- Heart failure (HF)  
- Pulmonary congestion (detected by physical exam, chest X‑ray, lung ultrasound)  
- B‑type natriuretic peptide (BNP)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- Creatine kinase‑MB (CK‑MB)  
- Coronary artery disease (CAD)  
- Coronary stenosis (≥50 %)  
- Left bundle branch block (LBBB)  
- Systolic blood pressure (SBP)  
- Heart rate (beats per minute)  
- Age thresholds (≥65 y, 65‑74 y, ≥75 y)  
- Diabetes mellitus  
- Hypertension  
- Angina (≥3 risk factors)  
- Aspirin use (prior 7 days)  
- Revascularization (urgent)  
- Routine invasive vs. selective invasive approach  
- Mortality / death (in‑hospital, 14‑day, 30‑day, 6‑month, 1‑year, 3‑year)  
- Cardiovascular events  
- Serial testing (0 h and 1‑2 h or 3‑6 h)  
- Risk stratification tools  
- Risk factors for CAD  
- Time to treatment (>4 h)  
- Weight (<67 kg)  
- Biomarkers (cardiac and non‑cardiac)  
- Serum creatinine  
- ST‑segment deviation (≥0.5 mm)  
- Cardiac arrest on admission  
- Clinical decision pathways (CDPs)  
- Negative predictive value (NPV)  
- High‑sensitivity assay vs. conventional cTn assay  
- Troponin assay characteristics (analytical characteristics)  

Page 16 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- B‑type Natriuretic Peptide (BNP)  
- Heart Failure (HF)  
- Major Adverse Cardiac Events (MACE)  
- Cardiogenic Shock  
- Acute Myocardial Infarction (AMI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Cardiac Arrest (including out‑of‑hospital cardiac arrest, OHCA)  
- Return of Spontaneous Circulation (ROSC)  
- Emergency Medical Services (EMS)  
- Emergency Department (ED)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Mechanical Circulatory Support (MCS)  
- Revascularization  
- PCI‑capable Hospital / PCI‑capable Center  
- Advanced Therapies (e.g., MCS)  
- Coronary Angiography  
- Risk Stratification / Risk Scores  
- Shock Severity Scales (e.g., SCAI shock stages)  
- ARREST Trial (Advanced Reperfusion Strategies for Patients With Out‑of‑Hospital Cardiac Arrest and Refractory Ventricular Fibrillation)  
- CARES Registry (Cardiac Arrest Registry to Enhance Survival)  
- Ventricular Fibrillation (VF)  
- Non‑shockable Rhythm  
- Bystander Cardiopulmonary Resuscitation (CPR)  
- Cardiopulmonary Resuscitation (CPR) Duration >30 min  
- Arterial pH < 7.2  
- Lactate > 7 mmol/L  
- Age > 85 years  
- End‑Stage Renal Disease / Renal Failure  
- Comatose vs. Non‑comatose Status  
- Neurologic Status (e.g., normal, partial/minimal response)  
- Electrocardiogram (ECG) – ST‑segment Elevation  
- Survival to Hospital Discharge  
- Observational Studies (outcome data)  
- Reperfusion Therapy  
- Shock‑related Mortality  
- Triage to PCI‑capable Facility  
- “Revascularization in ACS With Cardiogenic Shock” (Section 8.1)  
- “MCS in Patients With ACS and Cardiogenic Shock” (Section 8.2)  

Page 17 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Cardiac arrest  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Emergency coronary angiography  
- Delayed coronary angiography  
- Invasive therapies  
- Oxygen therapy / supplemental oxygen  
- Hypoxia (oxygen saturation < 90 %)  
- Oxygen saturation ≥ 90 % (normoxia)  
- Myocardial oxygen supply  
- Anginal symptoms  
- Cardiovascular outcomes  
- Myocardial injury  
- Vasoconstriction  
- Oxidative stress  
- AVOID trial (Air Versus Oxygen in ST‑Segment‑Elevation Myocardial Infarction)  
- DETO2X‑AMI trial (Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction)  
- Rehospitalization with MI  
- Analgesics  
- Chest pain  
- Sympathetic activation  
- Nitrates  
- Opiates  
- Coronary revascularization  
- Hemodynamically stable  
- Comatose after cardiac arrest  
- 12‑lead ECG  
- ST‑segment elevation (on ECG)  
- Neurologic prognosis (favorable / unfavorable)  
- In‑hospital survival  
- 6‑month survival  
- Neurologic recovery  
- Dialysis‑related disease (patients on dialysis)  
- Standard medical therapies for STEMI and NSTE‑ACS  
- Oxygen saturation target range (94 %–96 %)  

Page 18 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Percutaneous Coronary Intervention (PCI)  
- P2Y12 inhibitors  
- Non‑aspirin Nonsteroidal Anti‑Inflammatory Drugs (NSAIDs)  
- Major Adverse Cardiovascular Events (MACE)  
- Aspirin (loading dose, low‑dose, full‑dose)  
- Antiplatelet therapy  
- Atherothrombotic events  
- Vascular death  
- Acute Myocardial Infarction (AMI) / Myocardial Infarction (MI)  
- Stroke  
- Dual Antiplatelet Therapy (DAPT)  
- Anticoagulant therapy  
- Aspirin hypersensitivity  
- Aspirin desensitization  
- Platelet thromboxane A₂ suppression  
- Gastrointestinal bleeding  
- Nitroglycerin (sublingual, intravenous)  
- Hemodynamically stable patient  
- Systolic Blood Pressure (SBP)  
- Right‑ventricular (RV) infarction  
- Pulmonary edema  
- Morphine (IV)  
- Fentanyl (IV)  
- Phosphodiesterase‑5 (PDE5) inhibitors (avanafil, sildenafil, vardenafil, tadalafil)  
- Cardiac chest pain (analgesic treatment options)  
- Anti‑ischemic medications  
- Secondary prevention (post‑MI)  
- Invasive vs. non‑invasive management strategies  
- Hemodynamic tolerability  
- Tachyphylaxis (to nitrates)  
- Anticoagulation post‑discharge  
- Loading dose (aspirin, P2Y12 inhibitor)  
- Maintenance dose (aspirin)  
- Oral vs. rectal vs. intravenous drug administration  
- Platelet inhibition  
- Coronary events  
- Vascular events  
- Cardiovascular risk reduction  
- Bleeding risk (minor, major)  
- Drug‑drug interactions (e.g., nitrates with PDE5 inhibitors)  

Page 19 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation acute coronary syndromes (NSTE‑ACS)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Myocardial infarction (MI)  
- Major adverse cardiovascular events (MACE)  
- Major bleeding  
- Aspirin (low‑dose 75‑100 mg, high‑dose 81 mg/325 mg)  
- Ticagrelor  
- Prasugrel  
- Clopidogrel  
- Oral P2Y12 inhibitors  
- Platelet P2Y12 receptor antagonists  
- Platelet aggregation  
- Platelet inhibition  
- Percutaneous coronary intervention (PCI)  
- Primary percutaneous coronary intervention (PPCI)  
- Stent thrombosis  
- Fibrinolytic therapy  
- Stroke  
- Transient ischemic attack (TIA)  
- Coronary artery revascularization  
- Chronic coronary disease  
- Antiplatelet therapy  
- Loading dose  
- Maintenance dose  
- Invasive strategy  
- Angiography  
- Upstream treatment  
- Net clinical outcomes  
- Bleeding risk  
- Age‑adjusted dosing  
- Body‑weight‑adjusted dosing  
- Contraindication / contraindicated  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)  

Page 20 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation ACS (NSTE‑ACS)  
- Myocardial infarction (MI)  
- Major adverse cardiovascular events (MACE)  
- Stent thrombosis  
- Coronary artery bypass graft (CABG) surgery  
- Percutaneous coronary intervention (PCI)  
- Dual antiplatelet therapy (DAPT)  
- P2Y12 inhibitors (oral)  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Aspirin (ASA)  
- Fibrinolytic therapy  
- Transient ischemic attack (TIA)  
- Stroke  
- Bleeding risk / bleeding complications  
- Dyspnea (subjective transient)  
- Platelet inhibition (pharmacodynamic effect)  
- Platelet activation  
- Net clinical benefit (MACE + bleeding)  
- Net harm (in specific subgroups)  
- Age ≥ 75 years (dose‑reduction consideration)  
- Body weight < 60 kg (dose‑reduction consideration)  
- Oral anticoagulant (contraindication for certain P2Y12 choices)  

Page 21 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑elevation ACS (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Cardiovascular death  
- Stroke  
- Major adverse cardiovascular events (MACE)  
- Stent thrombosis  
- P2Y12 inhibitors  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Non‑CABG major bleeding  
- Life‑threatening bleeding  
- High bleeding risk  
- Coronary artery bypass grafting (CABG)  
- Elective CABG  
- Urgent CABG  
- Percutaneous coronary intervention (PCI)  
- Invasive management strategy  
- Planned invasive strategy  
- Upstream therapy (pre‑PCI antiplatelet therapy)  
- Pretreatment (pre‑loading)  
- Loading dose  
- Antiplatelet therapy  
- Pharmacodynamic variability  
- Cytochrome P450 metabolism (prodrug activation)  
- Vascular death  
- All‑cause death  
- Ischemic events  
- Early invasive management (< 24 h)  
- Angiography (coronary anatomy assessment)  
- Randomized controlled trial (RCT)  
- Double‑blind trial  
- Placebo‑controlled trial  
- PLATO trial  
- TRITON‑TIMI 38 trial  
- CURE trial  
- Composite endpoint (cardiovascular death, MI, or stroke)  

Page 22 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Stent thrombosis  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Recurrent myocardial infarction (MI)  
- Stroke  
- All‑cause death  
- Bleeding (major and minor)  
- P2Y12 inhibitor  
- Prasugrel  
- Ticagrelor  
- Clopidogrel  
- Aspirin  
- Fibrinolytic therapy / thrombolysis  
- Occluded infarct‑related artery  
- Urgent revascularization  
- Metoprolol  
- Cangrelor (intravenous P2Y12 inhibitor)  
- Intravenous P2Y12 inhibition  
- Coronary artery bypass grafting (CABG)  
- Platelet inhibition / platelet function restoration  
- Periprocedural ischemic events  
- Loading dose (e.g., clopidogrel 300 mg)  
- Maintenance dose (e.g., clopidogrel 75 mg daily)  
- TRITON‑TIMI 38 trial  
- PLATO trial  
- CLARITY‑TIMI 28 trial  
- COMMIT trial  
- ACC/AHA/SCAI Guideline for Coronary Artery Revascularization  
- Reperfusion (coronary reperfusion)  
- Angiography  
- Ischemic events (early recurrent ischemic events)  
- Evidence Table / Level of Evidence (LOE)  
- Coronary artery disease (CAD) (implicit throughout)  

Page 23 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Ischemia‑driven revascularization  
- Stent thrombosis  
- Percutaneous Coronary Intervention (PCI)  
- Large thrombus burden  
- No‑reflow phenomenon  
- Slow flow  
- Large anterior STEMI  
- Distal embolization of thrombus  
- Coronary artery revascularization  
- Drug‑eluting stents (DES)  
- Bleeding risk / bleeding complications  
- Platelet aggregation  
- Platelet cross‑linking  
- Fibrinogen  
- von Willebrand factor  

**Pharmacologic agents / drug classes**  
- Cangrelor (intravenous P2Y12 inhibitor)  
- Clopidogrel (oral P2Y12 inhibitor)  
- Prasugrel (oral P2Y12 inhibitor)  
- Ticagrelor (oral P2Y12 inhibitor)  
- Glycoprotein IIb/IIIa receptor inhibitors (intravenous or intracoronary)  
  - Abciximab  
  - Eptifibatide  
  - Tirofiban  

**Clinical trials / studies**  
- CHAMPION PHOENIX trial  
- CHAMPION PLATFORM trial  
- CHAMPION PCI trial  
- Pooled analysis of CHAMPION trials  

**Guidelines / recommendations**  
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization  
- 2025 Acute Coronary Syndromes Guideline (Circulation)  

**Procedural terms**  
- Intravenous bolus  
- Intravenous infusion (≥ 2 hours)  
- Intracoronary administration  
- “Upstream” administration of glycoprotein IIb/IIIa inhibitors  
- Transition from intravenous cangrelor infusion to oral P2Y12 inhibitor  
- Loading dose (e.g., clopidogrel 600 mg, prasugrel 60 mg, ticagrelor 180 mg)  
- Immediate loading after discontinuation of cangrelor  

**Outcome endpoints**  
- All‑cause death  
- Ischemic events  
- Infarct size  
- Thrombus resolution  

These terms capture the principal heart‑disease concepts, conditions, interventions, pharmacologic agents, trials, and guideline references presented in the excerpt.

Page 24 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑segment Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI) – Type 1 MI  
- Coronary atherothrombosis  
- Coronary spasm  
- Stress cardiomyopathy  
- Myocarditis  
- Major Adverse Cardiovascular Events (MACE)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Coronary angiography (invasive coronary angiography)  
- Glycoprotein IIb/IIIa inhibitor (e.g., eptifibatide)  
- Eptifibatide  
- P2Y12 inhibitors (e.g., clopidogrel)  
- Clopidogrel  
- Unfractionated heparin (UFH)  
- Enoxaparin (low‑molecular‑weight heparin)  
- Fondaparinux  
- Bivalirudin (direct thrombin inhibitor)  
- Argatroban (direct thrombin inhibitor)  
- Heparin‑induced thrombocytopenia (HIT)  
- Thrombin generation  
- Platelet aggregation  
- Fibrinolytic therapy (thrombolysis)  
- Reperfusion therapy  
- Intravenous anticoagulation  
- Parenteral anticoagulation  
- Catheter thrombosis  
- Vascular access site considerations  
- Renal function considerations  
- Antiplatelet agents  
- Anticoagulant agents  
- Early invasive approach  
- Upstream anticoagulant therapy  
- Adjunctive therapy (adjunctive glycoprotein IIb/IIIa inhibition)  
- Procedural outcomes  
- Periprocedural myocardial necrosis  
- Ischemic events  
- Bleeding complications  
- Mortality reduction  
- Revascularization (including PCI and CABG)  
- Hospital stay (duration of anticoagulation)  
- Diagnostic reclassification (e.g., to non‑atherothrombotic ACS)  

Page 25 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Unstable Angina  
- Myocardial Infarction (MI)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Dual Antiplatelet Therapy (DAPT)  
- Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Heparin‑Induced Thrombocytopenia (HIT)  
- Unfractionated Heparin (UFH)  
- Low‑Molecular‑Weight Heparin (LMWH)  
- Enoxaparin  
- Fondaparinux  
- Bivalirudin (direct thrombin inhibitor)  
- Antithrombin  
- Factor Xa inhibition  
- Activated Clotting Time (ACT)  
- Activated Partial Thromboplastin Time (aPTT)  
- Creatinine Clearance (CrCl)  
- Catheter Thrombosis (guiding‑catheter thrombus)  
- Bleeding Academic Research Consortium (BARC) bleeding criteria  
- Ischemic events  
- Reinfarction  
- Thrombin activity  
- Activated Protein C  
- Fibrinolytic therapy  
- Antiplatelet therapy (e.g., aspirin)  
- Anticoagulation  
- Thrombus formation  
- Protamine (heparin reversal agent)  
- OASIS‑5 trial (Fondaparinux in high‑risk NSTE‑ACS)  
- BRIGHT‑4 trial (Bivalirudin vs. Heparin in STEMI)  
- Meta‑analysis (comparative efficacy/safety)  
- Relative risk (RR)  
- Confidence interval (CI)  
- Early revascularization  
- Radial access (PCI)  
- Composite endpoint (all‑cause death or BARC bleeding)  

Page 26 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Bivalirudin  
- Unfractionated Heparin (UFH)  
- Glycoprotein IIb/IIIa inhibitors  
- Major bleeding  
- Major Adverse Cardiac Events (MACE)  
- Bleeding Academic Research Consortium (BARC) types 3‑5  
- ACUITY trial (A Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes)  
- MATRIX trial (Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX)  
- Enoxaparin (low‑molecular‑weight heparin)  
- ATOLL trial (Acute Myocardial Infarction Treated with Primary Angioplasty and Intravenous Enoxaparin or Unfractionated Heparin)  
- Death (all‑cause mortality)  
- Myocardial Infarction (MI)  
- Procedural failure  
- Net clinical benefit (death, MI, or major bleeding)  
- Fondaparinux  
- Catheter thrombosis (guiding‑catheter thrombus)  
- OASIS‑5 trial (Outcomes of a Prospective Study of Enoxaparin vs. Standard Therapy in Acute ST‑Elevation Myocardial Infarction)  
- OASIS‑6 trial (The Safety and Efficacy of Fondaparinux vs. Control Therapy in Patients with STEMI)  
- Fibrinolytic therapy / thrombolytic therapy  
- GUSTO trial (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries)  
- ASSENT‑3 trial (Assessment of the Safety and Efficacy of a New Thrombolytic Regimen)  
- ExTRACT‑TIMI 25 study (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment‑Thrombolysis in Myocardial Infarction 25)  
- Tissue Plasminogen Activator (tPA)  
- Streptokinase  
- Non‑fatal recurrent MI  
- Reinfarction  
- Low‑molecular‑weight heparin (LMWH)  
- Ischemic outcomes / ischemic events  
- Bleeding events  
- Transradial access  
- Anticoagulant (parenteral and sub‑cutaneous)  
- Antithrombotic therapy  
- Guideline‑recommended post‑procedure infusion (2‑ to 4‑hour bivalirudin infusion)  
- Clinical endpoint (primary, secondary)  
- Hospital discharge (duration of therapy)  
- Intravenous anticoagulation  
- Sub‑cutaneous anticoagulation  
- Invasive vs. non‑invasive management strategies.

